CoolSculpting® and Sonja Morgan Partner to Talk Bikini Denial

DUBLIN, March 20, 2019 /PRNewswire/ -- Television personality on Bravo's "The Real Housewives of New York City", philanthropist, fashion lifestyle entrepreneur and mom, Sonja Morgan, continues her partnership with CoolSculpting, owned by Allergan plc, to talk about "Bikini Denial." Bikini Denial identifies the feeling that many woman get when realizing that swimsuit season has snuck up on her and she is not prepared to bare it all at the beach or pool until she frees herself of stubborn fat. According to a recent survey, the most common area women feel self-conscious about is their belly¹. CoolSculpting is FDA-cleared to reduce fat in the abdomen area, along with eight other areas of the body, and can target that unwanted fat without surgery and little to no downtime.

As the face of the program, Morgan joins CoolSculpting this spring to inspire women across the country to learn more about personalized body contouring to help them achieve their own desired results just in time for summer.

"I am thrilled to partner with CoolSculpting and educate women about Bikini Denial. It is true that any body is a bikini body, but many women feel like they need a little help sometimes," said Morgan. "This year, I decided to try CoolSculpting to reduce pockets of stubborn fat in my flank or muffin top area that are resistant to diet and exercise so I can be bikini-ready this season."

Morgan will share her personal self-care story on her social media channels and discuss her CoolSculpting experience at an in-person event in New York City on Wednesday, March 20, 2019, the first day of spring, where she will be joined by dermatologist Dr. Daniel Belkin of Laser & Skin Surgery Center of New York to educate attendees on the proven science of CoolSculpting^..

"We are privileged to continue our work with Sonja Morgan, evolving her efforts as the face of our 'Let's Get Real About Self-Care' program to openly discuss Bikini Denial," said Brent Hauser, Vice President, Sales and Marketing, Body Contouring, Allergan. "Sonja continues to share her CoolSculpting experience authentically through her natural humor, passion and wit."

Consumers can share their own Bikini Denial stories on social media using #BikiniDenial and also enter the Bikini Denial Sweepstakes for a chance to win a free CoolSculpting treatment. NO PURCHASE NECESSARY. A PURCHASE WILL NOT INCREASE YOUR CHANCES OF WINNING.  LEGAL RESIDENTS OF THE 50 UNITED STATES (D.C.) 18 YEARS AND OLDER. VOID WHERE PROHIBITED. Sweepstakes ends September 29, 2019. For Official Rules, prize descriptions and odds disclosure, visit https://info.coolsculpting.com/bikini-denial-sweepstakes-rules. Sponsor: ZELTIQ Aesthetics, Inc., 4410 Rosewood Drive, Pleasanton, CA 94588.

*CoolSculpting is the treatment doctors use most for non-invasive fat removal.

¹Findings based on results of a national online survey of n=1,006 Americans aged 18+ fielded from October 26 – November 6, 2018. The survey was designed by Ketchum Analytics and facilitated by Ipsos on behalf of Allergan plc. The overall margin of error is ±3.1% at the 95 level.

About the CoolSculpting Treatment

CoolSculpting is a non-surgical, clinically proven treatment that selectively reduces unwanted fat using a patented cooling technology. Cleared by the FDA, CoolSculpting works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue, and the treated fat cells are gone for good. In 2019, CoolSculpting was recognized for the sixth consecutive year by NewBeauty as a Choice Award winner. Millions of CoolSculpting treatments have been performed in more than 80 countries. CoolSculpting is available through a network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.

Uses

The CoolSculpting procedure is FDA-cleared for the treatment of visible fat bulges in the submental(under the chin) and submandibular (under the jawline) areas, thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll) and upper arm. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments. The CoolSculpting procedure is not a treatment for weight loss.

Important Safety Information

The CoolSculpting procedure is not for everyone. You should not have the CoolSculpting procedure if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria. Tell your doctor if you have any medical conditions including recent surgery, pre-existing hernia, and any known sensitivities or allergies.

During the procedure you may experience sensations of pulling, tugging, mild pinching, intense cold,tingling, stinging, aching, and cramping at the treatment site. These sensations subside as the area becomes numb. Following the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental or submandibular area treatment.

Rare side effects may also occur. CoolSculpting may cause a visible enlargement in the treated area which may develop two to five months after treatment and requires surgical intervention for correction.

Please see full Important Safety Information for additional information.

Be sure to follow CoolSculpting on Facebook, Twitter, Pinterest and YouTube.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS^®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

SOURCE Allergan plc

Related Links

www.allergan.com